AlfaKinetic
by Anervea
LandscapeMonitorCompareProfileAsk
principle

Nothing is shown without a source. When the data can’t answer, the product says so.

LB Pharmaceuticals
tenant
person

George Haig, PharmD

as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Study Director
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
AbbVie
Roles
Study Director
Trial investigator
no

Trials led

5
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01678755Phase 2Completed
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01655680Phase 2Completed
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
NCT01077700Phase 2Completed
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
NCT01095562Phase 2Completed
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
NCT01834638Phase 2Terminated

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
trial
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
trial
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
trial
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
trial
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
trial